紫杉醇通过CDK1/BRCA1通路使同源重组功能正常的卵巢癌细胞对PARP抑制剂敏感
本研究在HRP卵巢癌OVISE细胞中建立两种紫杉醇给药方案模型,发现紫杉醇抑制CDK1表达、削弱BRCA1磷酸化并降低同源重组活性,从而增加对PARP抑制剂的敏感性;免疫组化显示紫杉醇化疗后CDK1表达降低,且剂量密集方案降低更明显。
要点
- 紫杉醇抑制CDK1表达,削弱BRCA1磷酸化,降低同源重组活性。
- 同源重组活性降低后,HRP卵巢癌细胞对PARP抑制剂敏感性增加。
- 紫杉醇化疗后CDK1表达降低,剂量密集方案较常规方案降低更明显。
核心结论
- 紫杉醇可在HRP卵巢癌细胞中与PARP抑制剂协同作用,提示两者联合可能成为拓展PARP抑制剂用于上皮性卵巢癌的新治疗策略。
- 作者认为该发现为未来评估紫杉醇联合PARP抑制剂在HRP卵巢癌中疗效的转化性临床试验提供了线索。
研究设计与样本
- 在HRP卵巢癌OVISE细胞中建立两种不同紫杉醇给药方案的模型。
- 在有无PARP抑制剂条件下分析细胞生长抑制和同源重组活性。
- 通过抑制CDK1检查OVISE细胞中BRCA1磷酸化状态。
- 在接受以紫杉醇为基础的新辅助化疗的上皮性卵巢癌患者中评估CDK1表达。
主要发现
- 紫杉醇抑制OVISE细胞中CDK1表达,导致BRCA1磷酸化受损。
- 紫杉醇降低CDK1活性可减弱DNA损伤应答中的同源重组活性,从而增加对PARP抑制剂的敏感性。
- 免疫组化显示,紫杉醇化疗后采集的样本中CDK1表达较化疗前采集的样本降低。
- CDK1表达的降低在剂量密集紫杉醇方案中大于常规紫杉醇方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: An effective treatment strategy for epithelial ovarian cancer (EOC) with homologous recombination (HR)-proficient (HRP) phenotype has not been established, although poly (ADP-ribose) polymerase inhibitors (PARPi) impact the disease course with HR-deficient (HRD) phenotype. Here, we aimed to clarify the cellular effects of paclitaxel (PTX) on the DNA damage response and the therapeutic application of PTX with PARPi in HRP ovarian cancer. METHODS: Two models with different PTX dosing schedules were established in HRP ovarian cancer OVISE cells. Growth inhibition and HR activity were analyzed in these models with or without PARPi. BRCA1 phosphorylation status was examined in OVISE cells by inhibiting CDK1, which was reduced by PTX treatment. CDK1 expression was evaluated in EOC patients treated with PTX-based neoadjuvant chemotherapy. RESULTS: PTX suppressed CDK1 expression resulting in impaired BRCA1 phosphorylation in OVISE cells. The reduced CDK1 activity by PTX could decrease HR activity in response to DNA damage and therefore increase the sensitivity to PARPi. Immunohistochemistry showed that CDK1 expression was attenuated in samples collected after PTX-based chemotherapy compared to those collected before chemotherapy. The decrease in CDK1 expression was greater with dose-dense PTX schedule than with the conventional PTX schedule. CONCULSIONS: PTX could act synergistically with PARPi in HRP ovarian cancer cells, suggesting that the combination of PTX with PARPi may be a novel treatment strategy extending the utility of PARPi to EOC. Our findings provide cules for future translational clinical trials evaluating the efficacy of PTX in combination with PARPi in HRP ovarian cancer.
引用
- Yanaihara N, Yoshino Y, Noguchi D, et al. Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway. Gynecol Oncol. 2022. PMID: 36403366. doi:10.1016/j.ygyno.2022.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。